Christina Schjellerup Eickhardt-Dalbøge

7PUBLICATIONS
26CO-AUTHORS
Haematological tumoursCardiology (incl. cardiovascular diseases)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 17, 2026
Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.

|Nov 06, 2025
The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.

Morten Kranker Larsen, Vibe Skov, Lasse Kjær

|Sep 18, 2025
Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Isabella Diana Davidsen, Morten Kranker Larsen, Lea Löffler

|Aug 20, 2024
Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær

|Jan 16, 2024
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

Christina Schjellerup Eickhardt-Dalbøge, Henrik V Nielsen, Kurt Fuursted

|Sep 11, 2023
Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Christina Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Henrik V Nielsen

Pageof 2

Frequent Collaborators

6 joint publications

Vibe Skov

5 joint publications

Trine Alma Knudsen

5 joint publications

Christina Ellervik

5 joint publications

Hans Hasselbalch